BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 20164036)

  • 1. Inhibition of rhabdomyosarcoma's metastatic behavior through downregulation of MET receptor signaling.
    Lukasiewicz E; Miekus K; Kijowski J; Drabik G; Wilusz M; Bobis-Wozowicz S; Majka M
    Folia Histochem Cytobiol; 2009 Jan; 47(3):485-9. PubMed ID: 20164036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation.
    Miekus K; Lukasiewicz E; Jarocha D; Sekula M; Drabik G; Majka M
    Cell Death Dis; 2013 Jan; 4(1):e459. PubMed ID: 23328666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy.
    Jankowski K; Kucia M; Wysoczynski M; Reca R; Zhao D; Trzyna E; Trent J; Peiper S; Zembala M; Ratajczak J; Houghton P; Janowska-Wieczorek A; Ratajczak MZ
    Cancer Res; 2003 Nov; 63(22):7926-35. PubMed ID: 14633723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.
    Skrzypek K; Kusienicka A; Szewczyk B; Adamus T; Lukasiewicz E; Miekus K; Majka M
    Oncotarget; 2015 Oct; 6(31):31378-98. PubMed ID: 26384300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma.
    Strahm B; Durbin AD; Sexsmith E; Malkin D
    Clin Exp Metastasis; 2008; 25(1):1-10. PubMed ID: 17768666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion.
    Jaaks P; D'Alessandro V; Grob N; Büel S; Hajdin K; Schäfer BW; Bernasconi M
    PLoS One; 2016; 11(8):e0161396. PubMed ID: 27548722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting MET Receptor in Rhabdomyosarcoma: Rationale and Progress.
    Szewczyk B; Skrzypek K; Majka M
    Curr Drug Targets; 2017; 18(1):98-107. PubMed ID: 26674534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma.
    Diomedi-Camassei F; McDowell HP; De Ioris MA; Uccini S; Altavista P; Raschellà G; Vitali R; Mannarino O; De Sio L; Cozzi DA; Donfrancesco A; Inserra A; Callea F; Dominici C
    Clin Cancer Res; 2008 Jul; 14(13):4119-27. PubMed ID: 18593989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274.
    Hou J; Dong J; Sun L; Geng L; Wang J; Zheng J; Li Y; Bridge J; Hinrichs SH; Ding SJ
    J Transl Med; 2011 May; 9():64. PubMed ID: 21575221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors.
    Chadalapaka G; Jutooru I; Sreevalsan S; Pathi S; Kim K; Chen C; Crose L; Linardic C; Safe S
    Int J Cancer; 2013 Feb; 132(4):795-806. PubMed ID: 22815231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus-mediated siRNA targeting c-Met inhibits proliferation and invasion of small-cell lung cancer (SCLC) cells.
    Wang ZX; Lu BB; Yang JS; Wang KM; De W
    J Surg Res; 2011 Nov; 171(1):127-35. PubMed ID: 20338593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemia inhibitory factor: a newly identified metastatic factor in rhabdomyosarcomas.
    Wysoczynski M; Miekus K; Jankowski K; Wanzeck J; Bertolone S; Janowska-Wieczorek A; Ratajczak J; Ratajczak MZ
    Cancer Res; 2007 Mar; 67(5):2131-40. PubMed ID: 17332343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis.
    Sharp R; Recio JA; Jhappan C; Otsuka T; Liu S; Yu Y; Liu W; Anver M; Navid F; Helman LJ; DePinho RA; Merlino G
    Nat Med; 2002 Nov; 8(11):1276-80. PubMed ID: 12368906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice.
    Sakamoto S; Inoue H; Ohba S; Kohda Y; Usami I; Masuda T; Kawada M; Nomoto A
    Cancer Sci; 2015 Apr; 106(4):367-74. PubMed ID: 25640943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression.
    Chen Y; Takita J; Mizuguchi M; Tanaka K; Ida K; Koh K; Igarashi T; Hanada R; Tanaka Y; Park MJ; Hayashi Y
    Genes Chromosomes Cancer; 2007 Apr; 46(4):348-58. PubMed ID: 17243166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Studies of intercellular communication in human rhabdomyosarcoma cell lines of different metastatic potential].
    Zhang J; Zhang H; Bu H; Yang G; Li S; Guo L
    Zhonghua Bing Li Xue Za Zhi; 2001 Dec; 30(6):448-51. PubMed ID: 11866989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.
    Kim SJ; Johnson M; Koterba K; Herynk MH; Uehara H; Gallick GE
    Clin Cancer Res; 2003 Nov; 9(14):5161-70. PubMed ID: 14613995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
    MacDougall CA; Vargas M; Soares CR; Holzer RG; Ide AE; Jorcyk CL
    Prostate; 2005 Jul; 64(2):139-48. PubMed ID: 15678502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo.
    Lesko E; Gozdzik J; Kijowski J; Jenner B; Wiecha O; Majka M
    Anticancer Drugs; 2007 Nov; 18(10):1173-81. PubMed ID: 17893518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators.
    Yu Y; Khan J; Khanna C; Helman L; Meltzer PS; Merlino G
    Nat Med; 2004 Feb; 10(2):175-81. PubMed ID: 14704789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.